Pioglitazone and metformin in fixed dose combination

Takeda UK Ltd has introduced a fixed dose combination of pioglitazone (15mg) and metformin (850mg) under the brand name of Competact.

Competact is indicated for the treatment of type 2 diabetes, particularly in overweight patients, who are unable to achieve sufficient glycaemic control at maximally tolerated doses of metformin alone.

The usual dose is one tablet twice daily. Dose titration with pioglitazone added to the optimal dose of metformin should be considered before switching the patient to the fixed dose combination, but when clinically appropriate a direct switch from metformin monotherapy can be made. Pharmacokinetic studies in healthy volunteers have shown the fixed dose combination to be bioequivalent to the two drugs given as separate tablets.

Further information: Takeda UK Ltd, Takeda House, The Mercury Park, Wycombe Lane, High Wycombe, Buckinghamshire HP10 0HH. Tel: (01628) 537900.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in